References
- Bloom A. S. Effects of cannabinoids on neurotransmitter receptors in the brain. The Cannabinoids: Chemical, Pharmacologic and Therapeutic Aspects, S. Agurell, W. L. Dewey, R. E. Willette. Academic Press, Orlando 1984; 575–589
- Brennan M. J. W., Ruff P., Sandyk R. Efficacy of a combination of sodium valproate and baclofen in Meige's disease (Idiopathic orofacial dystonia). British Medical Journal 1982; 285: 853
- Burke R. E., Fahn S., Marsden C. D., Bressman S. B., Moskowitz C., Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 1985; 35: 73–77
- Clifford D. B. Tetrahydrocannabinol for tremor in multiple sclerosis. Annals of Neurology 1983; 13: 669–671
- Consroe P., Benedito M. A. C., Leite J. R., Carlini E. A., Mechoulam R. Effects of cannabidiol on behavioral seizures caused by convulsant drugs or current in mice. European Journal of Pharmacology 1982; 83: 293–298
- Cunha J. M., Carlini E. A., Pereira A. E., Ramos O. L., Pimentel C., Gagliardi R., Sanvito W. L., Lander N., Mechoulam R. Chronic administration of cannabidiol to healthy volunteers and epileptic patients. Pharmacology 1980; 21: 175–185
- Marsden C. D. Treatment of torsion dystonia. Disorders of Movement, Current Status of Modern Therapy, A. Barbeau. Lippincott, Philadelphia 1981; Vol. 8: 81–104
- Moss D. E., Montgomery S. P., Salo A. A., Steger R. W. Tetrahydrocannabinol effects on extrapyramidal motor behaviors in an animal model of Parkinson's disease. The Cannabinoids: Chemical, Pharmacologic, and Therapeutic Aspects, S. Agurell, W. L. Dewey, R. E. Willette. Academic Press, Orlando 1984; 815–822
- O'Shaughnessy W. B. On the preparation of Indian hemp or gunjah. Transactions of the Medical and Physical Society of Bombay. 1842; 8: 421–461
- Pakkenberg H., Pedersen B. Medical treatment of dystonia. Dyskinesia-Research and Treatment, D. E. Casey, T. N. Chase, A. V. Christensen, J. Gerlach. Springer-Verlag, Berlin 1985; 111–117
- Perry T. L. Levels of glutamine, glutamate and GABA in CSF and brain under pathological conditions. Glutamine, Glutamate and GABA in the Central Nervous System, L. Hertz, E. Kvamme, E. G. McGeer, A. Schousbee. Alan R. Liss, New York 1983; 581–594
- Petro D. J., Ellenberger C., Jr. Treatment of human spasticity with delta-9-tetrahydro-cannabinol. Journal of Clinical Pharmacology 1981; 21: 413s–416s
- Revuelta A. V., Cheney D. L., Wood P. L., Costa E. Gabergic mediation in the inhibition of hippocampal acetylcholine turnover rate elicited by delta-9-tetrahydrocannabinol. Neuropharmacology 1979; 18: 525–530
- Revuelta A. V., Moroni F., Cheney D. L., Costa E. Effect of cannabinoids on the turnover rate of acetylcholine in rat hippocampus, striatum and cortex. Naunyn-Schmiedeberg's Archives of Pharmacology 1978; 304: 107–110
- Reynolds J. R. Therapeutic uses and toxic effects of Cannabis indica. Lancet 1890; 1: 637–638
- Snider S. R., Consroe P. Treatment of Meige syndrome with cannabidiol. Neurology 1984; 34: 147, Suppl. 1
- Snider S. R., Consroe P. Beneficial and adverse effects of cannabidiol in a Parkinson patient with Sinemet-induced dystonic dyskinesia. Neurology 1985; 35: 201, Suppl 1
- Stahl S. M., Berger P. A. Bromocriptine, physostigmine, and neurotransmitter mechanisms in the dystonias. Neurology 1982; 32: 889–892